首页> 美国卫生研究院文献>Journal of Thoracic Disease >Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases 18 and 15 years after nephrectomy
【2h】

Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases 18 and 15 years after nephrectomy

机译:肾细胞癌的肺转移及时性消失:肾切除术后18和15年完全切除了异时转移

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Surgery is the only potentially curative therapeutic approach for renal cell carcinoma (RCC). RCC is resistant to most systemic therapies, including chemotherapy, radiotherapy, and hormonal therapy, having limited response to immunotherapy. Newer agents targeting angiogenesis, recommended in metastatic RCC, offer improved disease free and overall survival, stabilizing the disease, rather than having a curative effect.One of the most common sites of synchronous or metachronous RCC metastases is the lung. The five-year survival after resection of RCC pulmonary metastases ranged between 21% and 83%. Complete metastasectomy improves the prognosis and should be evaluated, despite improved results of newer systemic treatments.In surgically treated metachronous RCC pulmonary metastases, the reported disease free interval varied, but in the majority of cases it did not exceed five years. Surgical resection of RCC pulmonary metastases 15 or more years after nephrectomy is very rare. We report complete surgical resection of metachronous, multiple, unilateral clear cell RCC pulmonary metastases in two patients without enlarged mediastinal lymph nodes or extrapulmonary disease, 15 and 18 years after initial nephrectomy. Both patients had an uneventful recovery, and remain alive and well one year, and five months respectively, after metastasectomy.
机译:手术是治疗肾细胞癌(RCC)的唯一可能的治疗方法。 RCC对大多数全身疗法(包括化学疗法,放射疗法和激素疗法)有抵抗力,对免疫疗法的反应有限。在转移性RCC中推荐使用靶向血管生成的新型药物,以改善无病生存期和总体生存期,稳定疾病而不是起到治愈作用。同步或异时RCC转移最常见的部位之一是肺部。切除RCC肺转移后的五年生存率在21%至83%之间。尽管更新的全身治疗结果有所改善,但完整的转移瘤切除术仍改善了预后并应进行评估。在外科治疗的异时RCC肺转移瘤中,报告的无病间隔有所不同,但在大多数情况下不超过五年。肾切除术后15年或更长时间进行RCC肺转移的手术切除非常罕见。我们报道在初次肾切除术后15和18年,两名无纵隔淋巴结肿大或肺外疾病扩大的患者中,完成了异时,多发,单侧透明细胞RCC肺转移的完整手术切除。两名患者的转移均保持平稳,并在转移灶切除后分别存活了一年和五个月。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号